Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Gamida Cell Ltd. | CMO & CHIEF SCIENTIFIC OFFICER | Ordinary Shares | 656K | $1.02M | $1.55 | Jan 31, 2024 | Direct |
Gamida Cell Ltd. | CMO & CHIEF SCIENTIFIC OFFICER | Employee Share Option (Right to Buy) | 116K | Feb 8, 2023 | Direct | ||
Clovis Oncology, Inc. | Director | Stock Option (right to buy) | 83.2K | Jul 12, 2021 | Direct | ||
Tempest Therapeutics, Inc. | Director | Stock Option (right to buy) | 16K | Jun 13, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
TPST | Tempest Therapeutics, Inc. | Jun 13, 2024 | 1 | $0 | 4 | Jun 14, 2024 | Director |
GMDA | Gamida Cell Ltd. | Jan 31, 2024 | 1 | $0 | 4 | Feb 2, 2024 | CMO & CHIEF SCIENTIFIC OFFICER |
TPST | Tempest Therapeutics, Inc. | Jun 15, 2023 | 1 | $0 | 4 | Jun 20, 2023 | Director |
GMDA | Gamida Cell Ltd. | Feb 8, 2023 | 2 | $0 | 4 | Feb 10, 2023 | CMO & Chief Scientific Officer |
GMDA | Gamida Cell Ltd. | Nov 15, 2022 | 0 | $0 | 3 | Feb 10, 2023 | CMO & Chief Scientific Officer |
TPST | Tempest Therapeutics, Inc. | Jun 17, 2022 | 1 | $0 | 4 | Jun 22, 2022 | Director |
TPST | Tempest Therapeutics, Inc. | Aug 6, 2021 | 1 | $0 | 4 | Aug 10, 2021 | Director |
TPST | Tempest Therapeutics, Inc. | Aug 6, 2021 | 0 | $0 | 3 | Aug 10, 2021 | Director |
CLVS | Clovis Oncology, Inc. | Jul 12, 2021 | 1 | $0 | 4 | Jul 13, 2021 | Director |
CLVS | Clovis Oncology, Inc. | Jul 12, 2021 | 0 | $0 | 3 | Jul 13, 2021 | Director |